<DOC>
	<DOCNO>NCT01114620</DOCNO>
	<brief_summary>The purpose study comply post marketing condition exceptional approval Arepanrix™ Japan ass immunogenicity safety GSK Biologicals ' H1N1 influenza vaccine healthy Japanese adult 65 year age old .</brief_summary>
	<brief_title>Study GSK Biologicals ' Influenza Vaccine Arepanrix™ Japanese Adults 65 Years Age Older</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Japanese male female adult 65 year age old time vaccination . Subjects investigator believe comply requirement protocol . Written inform consent obtain subject . Good general health assess medical history physical examination . Access consistent mean telephone contact , may either home workplace , land line mobile , NOT pay phone multipleuser device . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception 2 month study vaccination . Use investigational nonregistered product ( drug vaccine ) within 30 day precede dose study vaccine , plan use study period . History previous administration pandemic H1N1 vaccine . Presence significant acute chronic , uncontrolled medical psychiatric illness . Presence evidence substance abuse neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence axillary temperature &gt; = 37.5 °C , acute symptom great `` mild '' severity schedule date vaccination . Diagnosed cancer , treatment cancer within three year . Persons history cancer diseasefree without treatment three year eligible . Persons history histologicallyconfirmed basal cell carcinoma skin successfully treat local excision accept may enrol , histologic type skin cancer exclusionary . Women diseasefree three year treatment breast cancer receive longterm prophylactic tamoxifen except may enroll . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Chronic administration ( defined 14 day total ) immunosuppressant immune modify drug within 6 month study enrolment plan administration study period . For corticosteroid , mean dose equivalent 10 mg/day prednisone equivalent administer &gt; 2 week . Topical , intraarticularly inject , inhaled glucocorticoid , topical calcineurin inhibitor imiquimod allow . Receipt immunoglobulins and/or blood product within three month study enrolment plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin outside 24 hour prior vaccination eligible . Persons receive prophylactic antiplatelet medication , e.g. , lowdose aspirin , without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder history GuillainBarré syndrome within 6 month receipt seasonal influenza vaccination . Administration vaccine within 30 day vaccination plan administration blood sample Day 21 within 30 day prior blood sample Day 182 . Any known suspected allergy constituent influenza vaccine component use manufacturing process study vaccine ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Excessive underweight [ Body Mass Index ( BMI ) &lt; 18.5 ] excessive obesity ( BMI &gt; = 30 ) . Any condition , opinion investigator , prevents subject participate study . Clinically virologically confirm influenza infection within 12 month precede study start .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>elderly</keyword>
	<keyword>post-marketing</keyword>
	<keyword>H1N1</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>pandemic influenza</keyword>
</DOC>